DocGo (DCGO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors: Vina Leite and James M. Travers, with board recommendation to vote for both.
Advisory vote to approve named executive officer compensation, recommended for approval.
Proposal to approve a reverse stock split at a ratio between 1-for-5 and 1-for-10, with a proportionate reduction in authorized shares, at the board's discretion.
Amendment to the certificate of incorporation regarding waiver of corporate opportunities, recommended for approval.
Amendment to limit liability of certain officers as permitted by Delaware law, recommended for approval.
Ratification of Urish Popeck & Co., LLC as independent auditor for the year ending December 31, 2026.
Board of directors and corporate governance
Board recommends all proposals, including director elections and amendments, for shareholder approval.
Board retains discretion on timing and ratio of the proposed reverse stock split.
Executive compensation and say-on-pay
Advisory vote on executive compensation for named executive officers is included as a key agenda item.
Latest events from DocGo
- Proxy seeks approval for director elections, reverse stock split, and key governance amendments.DCGO
Proxy filing22 Apr 2026 - Key proposals include director elections, a reverse stock split, and governance amendments.DCGO
Proxy filing10 Apr 2026 - 2026 guidance raised on core growth and SteadyMD gains, with H2 profitability targeted.DCGO
Q4 202516 Mar 2026 - Scaling tech-enabled mobile healthcare with record volumes and strong growth outlook.DCGO
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - All proposals passed, with strong financials and strategic growth initiatives outlined.DCGO
AGM 20243 Feb 2026 - Q2 revenue up 31% to $164.9M, net income and margins rose, and cash flow guidance increased.DCGO
Q2 20242 Feb 2026 - Strong Q2 growth, cash gains, and a shift to sustainable health programs drive 2024 optimism.DCGO
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Transitioning from migrant contracts, the company targets $400M in core business growth for 2025.DCGO
Stifel 2024 Cross Sector Insight Conference1 Feb 2026 - Core mobile health business is set for strong growth as migrant revenue phases out.DCGO
15th Annual Midwest IDEAS Investor Conference23 Jan 2026